(CercleFinance.com) – GSK today announced positive results from an interim efficacy analysis of a phase III trial evaluating belantamab mafodotine as a second-line treatment for relapsed or refractory multiple myeloma.
The trial met its primary endpoint of progression-free survival (PFS) and showed that belantamab mafodotin, when combined with bortezomib plus dexamethasone (BorDex), significantly prolonged the time to disease progression or death compared to daratumumab plus BorDex, an existing standard of care for relapsed/refractory multiple myeloma.
‘We are particularly encouraged by the potential of belantamab mafodotin, when combined with BorDex, to address the high unmet need in relapsed/refractory multiple myeloma, given the head-to-head comparison with the standard drug-based regimen. daratumumab’, commented Hesham Abdullah, Senior Vice President, Global Head of Oncology, R&D at GSK.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
